Keywords: Fabry disease; Diagnosis; Mutation; Management; Treatment; ACEI; angiotensin converting enzyme inhibitor; ARB; angiotensin receptor blocker; AV; atrioventricular; α-Gal A; α-galactosidase A; CKD; chronic kidney disease; CNS; central nervous system; CT;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: α-gal A; α-galactosidase A; Cr; creatinine; ERT; enzyme replacement therapy; FD; Fabry disease; GCL; glutamate cysteine ligase; Gb3; globotriaosylceramide; GLA; α-galactosidase A coding gene; GPx; glutathione peroxidase; GR; glutathione reductase; GSH;
Keywords: α-Gal A; alpha-galactosidase A; CKD EPI; Chronic Kidney Disease Epidemiology Collaboration; eGFR; estimated glomerular filtration rate; ERT; enzyme replacement therapy; FOS; Fabry Outcome Survey; LVH; left ventricular hypertrophy; LVMI; left ventricular
Keywords: α-Gal A; alpha-galactosidase A; CKD; chronic kidney disease; CRF; chronic renal failure; DBS; dried blood samples; DNA; deoxyribonucleic acid; DP; dialysis patients; EDTA; ethylenediaminetetraacetic acid; FD; Fabry disease; Gb3; globotriaosylceramide; GF
Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ
Keywords: α-Gal A; alpha-galactosidase A; FD; Fabry disease; DGJ; 1-deoxygalactonojirimycin; VUS; variants of unknown significance; 1-Deoxygalactonojirimycin; DGJ; De novo mutation; Atypical variants; Lipofectamine; Site-directed mutagenesis;
The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein
Keywords: 4-MUG; 4-methylumbelliferone α-d-galactopyranoside; GalNAc; N-acetyl-d-galactosamine; α-Gal A; alpha-Galactosidase A; α-syn; alpha-synuclein; ALP; autophagy-lysosome pathway; Cat B; cathepsin B; Cat D; cathepsin D; Gb3; globotriaosylceramide; lyso-Gb3;
The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome
Keywords: α-gal A; α-galactosidase A; Gb3; globotriaosylceramide; Gb2; galabiosylceramide; XCI; X-chromosomal inactivation; LVH; left ventricular hypertrophy; α-Galactosidase A; Globotriaosylceramide; Intellectual disability; X-chromosomal inactivation; Methylat
Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients
Keywords: OMIM; Online Mendelian Inheritance in Man; α-GAL A; α-galactosidase A; ERT; enzyme replacement therapy; CFDI; Canadian Fabry Disease Initiative; Gb3 or GL-3; globotriaosylceramide; CTH; ceramide trihexoside; Ga2; galabiosylceramide; CDH; ceramide dihexo
The prevalent deep intronic c. 639Â +Â 919 GÂ >Â A GLA mutation causes pseudoexon activation and Fabry disease by abolishing the binding of hnRNPA1 and hnRNP A2/B1 to a splicing silencer
Keywords: α-Gal A; α-galactosidase A enzyme; ESE; exonic splicing enhancer; ESS; exonic splicing silencer; FGB; fibrinogen β gene; GLA; α-galactosidase A gene; hnRNP A1, A2/B1, F, and H; heterogeneous ribonucleoprotein A1, A2/B1, F, and H; NMD; nonsense-mediate
Associate editor: O. BinahInherited cardiomyopathies-Novel therapies
Keywords: Hypertrophic cardiomyopathy; Dilated cardiomyopathy; Arrhythmogenic cardiomyopathy; Amyloidosis; Duchenne muscular dystrophy; Gene therapy; ACM; arrhythmogenic cardiomyopathy; AON; antisense oligo-nucleotide; α-Gal A; α-galactosidase A; BMD; Becker musc
Novel alpha-galactosidase A mutation in a female with recurrent strokes
Keywords: AFD; Anderson-Fabry disease; GL-3; globotriaosylceramide; cDNA; complementary DNA; 3â² UTR; three prime untranslated region; pAS; polyadenylation signal; CT; computed tomography; magnetic resonance imaging; MRI; DBFP; Dried Blood Filter Paper; K,EDTA;
Diagnostic dilemma: A young woman with Fabry disease symptoms, no family history, and a “sequencing cryptic” α-galactosidase a large deletion
Keywords: α-Gal A; α-galactosidase A; GL-3 or Gb3; globotriaosylceramide; ERT; enzyme replacement therapy; MLPA; Multiplex Ligation-dependent Probe Amplification; PCR; polymerase chain reaction; Fabry disease; Lysosomal storage disease; α-galactosidase A; Gene r
Guidelines to Diagnosis and Monitoring of Fabry Disease and Review of Treatment Experiences
Keywords: α-Gal A; α-Galactosidase A; CKD; Chronic kidney disease; eGFR; Estimated glomerular filtration rate; ERT; Enzyme replacement therapy; GLA; α-Galactosidase A gene; GL-3; Globotriaosylceramide; GL-2; Lactosylceramide; HDL; High-density lipoprotein; LDL;
Radiological Evidence of Early Cerebral Microvascular Disease in Young Children with Fabry Disease
Keywords: CNS; Central nervous system; ERT; Enzyme replacement therapy; FLAIR; Fluid attenuated inversion recovery; α-Gal A; α Galactosidase A; MRI; Magnetic resonance imaging;